# Hub Monitor Review — 2026-09-23

**Run type:** automated review (read-only; no existing files modified)
**Scan time:** 2026-09-23 02:32 CDT (07:32 UTC)
**Previous review:** `monitor_report_2026-09-22.md`

---

## 0. Lead findings

**1. Yesterday's report made the same timing error it diagnosed, and one of its lead findings was wrong.** `[Certain]`
It said "Zero files carry a 2026-09-22 timestamp as of 07:37 UTC... four hours past the pipeline's usual 03:1x window."
That compared a **UTC** scan time with file mtimes shown in **CDT** (the sandbox clock is `America/Chicago`, UTC−5).
07:37 UTC was 02:37 CDT. The 09-22 pipeline then wrote ~150 files between **03:16 and 03:45 CDT**, *after* the monitor had run.

```
CDT   02:00        02:40            03:16 ─────────── 03:45
        │            │ monitor runs     │ pipeline writes │
        │            ▼                  ▼                 ▼
 09-21  ─────────────●──────────────────████████████████──
 09-22  ─────────────●──────────────────████████████████──
 09-23  ─────────────● (this run, 02:32) … pipeline not yet run
```

**No 09-23 output exists yet, and none is expected before about 03:15 CDT. That is not a failure.** This is the third day in a row the monitor has run before the pipeline. The P0 fix from yesterday still stands: move this task to ≥04:30 CDT (09:30 UTC).

**2. The freshness gate passes while trial data is 68 days old.** `[Certain]`
`report_freshness_audit.json` (09-22) reports `reports_failing: 0`, but it checks only **2 reports**: the gap report and the PubMed summary.
It never checks `clinical_trials_latest.json` (07-17, 68 days) or `clinical_trials_summary.md`. The gate is green because the stale file is outside its scope. Add the trials alias to its scope, or expect this to stay invisible.

**3. The trial corpus misses retatrutide's pivotal Phase 3 trials.** `[Certain]`
TRANSCEND-T2D-1 (**NCT06354660**) and TRIUMPH-1 (**NCT05929066**) have **0 matches** in the 894-trial 09-06 snapshot.
Yesterday's report tied the TRANSCEND results to NCT06260722. That is a different retatrutide trial (a head-to-head against semaglutide), so the "has_results flag not catching publications" argument used the wrong trial.
The real problem is a coverage gap. The acquisition query is dropping completed Phase 3 trials of a tracked therapy.

---

## 1. File system status

| File | Last modified (CDT) | Age | Verdict |
|---|---|---:|---|
| `agent_state.json` (`last_run: 2026-09-22`) | 09-22 03:45 | 1d | current |
| `pubmed_recent_latest.json` (= snapshot 09-22) | 09-22 03:42 | 1d | current |
| `literature_gap_report.md` | 09-22 03:40 | 1d | current, but it was **re-rendered from 09-19 data** |
| `literature_gap_data.json` | 09-19 03:26 | 4d | current |
| `clinical_trials_snapshot_2026-09-06.json` | 09-06 | **17d** | **stale** |
| `clinical_trials_latest.json` | 07-17 | **68d** | **broken alias** |
| `hub_monitor_report.md` | 07-17 | **68d** | **stale** (script not running) |
| `Diabetes_Research_Tracker.xlsx` | 07-17 | **68d** | **stale** |

The 09-22 run's own log (`agent_state.run_history[-1]`) is worth reading. The pipeline found that `run_quality_improvements` treated a gate that printed `[FAIL]` but exited 0 as passing. It also found that `audit_nct_identifiers` checked only the first mention of each NCT.
Fixing both surfaced 8 wrong registry records in the Trial Equity Mapper. One was a completely wrong trial: NCT04262479 was labelled as the n=330 DIAGNODE-3, but it is a 14-patient Norwegian LADA study. That record has been repaired. `changes_pushed: false`.

## 2. Clinical trial changes

**No new trial data since 09-06. Nothing to diff.** The 51-day diff in yesterday's report still holds. Carry-forward priorities:

- NCT07797335: Novo AMBITION 7 (zenagamtide), Phase 3, RECRUITING
- NCT07804849: oral verapamil in pediatric new-onset T1D, Phase 2/3. This is Tier 1 Drug Repurposing.
- NCT06334133: cadisegliatin Phase 3 in T1D, enrollment closed

**Coverage gaps (new today):** the retatrutide Phase 3 program is missing (§0.3). FINE-ONE is also absent by name (0 matches), and it now has an FDA approval (§5).
`[Likely]` The trial query is filtered in a way that excludes completed or industry pivotal studies. Audit the query's status and condition filters before trusting any "0 trials" result.

## 3. PubMed highlights (09-20 → 09-22)

32 new papers and 34 dropped (152 total). The 30-day window slides and each domain is capped at 10 papers (`domain_retmax: 10`), so this is a **sample of about 1,068 matches, not a census**. Don't read turnover as a trend.

**New cross-domain papers:**

| PMID | Domains | Title (abridged) | Relevance |
|---|---|---|---|
| 42763732 | GLP-1 + **CagriSema** | CagriSema: systematic review and meta-analysis of RCTs | Evidence synthesis for a tracked therapy (SILVER candidate) |
| 42767751 | T1D Immunotherapy + **teplizumab** | SIRENA protocol: Italian multicentre islet-autoimmunity cohort (*BMJ Open*) | Stage 1–2 screening infrastructure |
| 42766561 | Biomarker + Microbiome | Youth-derived FMT in adults with T1D | Microbiome × T1D |
| 42764398 | Biomarker + **Multi-Omics** | Aqueous-humour metabolomics in persistent DME | Tier 1 Multi-Omics axis |
| 42767537 | Biomarker + Complications | S100A8/A9–TMEM24 axis in early diabetic nephropathy | DKD target |
| 42764204 | GLP-1 + Remission | Longitudinal systems modelling: tirzepatide vs. semaglutide (*JCEM*) | Computational, similar to our methods |

**Single-domain papers worth a look:**

- 42766004, harmine and beta-cell identity (*Diabetologia*). A repurposing candidate for beta-cell regeneration.
- 42764397, a DPP6 PET tracer for imaging transplanted islets. Islet Transplant axis.
- 42765135, "Closing the rural diabetes research gap". Health Equity axis.

**Therapy counts, 09-20 → 09-22:** CagriSema 3→4, teplizumab 6→7, baricitinib 3→2, retatrutide 13→12, dapagliflozin 46→44, others flat. **zimislecel is still 0.** The alias bug (VX-880) is unfixed.

**Domain volume:** flat. The three domains stuck at exactly 3 (Drug Repurposing, Epigenetics, GLP-1 Pharmacogenomics) are **unchanged for 3 consecutive snapshots**. That makes a broken query more likely than a real signal. `[Likely]`

## 4. Gap analysis summary

Unchanged. The report was re-rendered on 09-22 from data dated 09-19. Validation level: **BRONZE**.

| # | Intersection | Joint pubs | Tier 1 |
|---|---|---:|---|
| 1 | Beta Cell Regen × Health Equity | 0 | #6 Equity |
| 2 | Insulin Resistance × Islet Transplant | 1 | — |
| 3 | Islet Transplant × Drug Repurposing | 0 | #4 Repurposing (only gap with manual re-verification) |
| 4 | Islet Transplant × Health Equity | 0 | #6 Equity |
| 5 | Gene Therapy × LADA | 0 | — |

**New caveat: the score is saturated.** `[Certain]` Twelve pairs tie at 100.0, including pairs with 1–3 joint publications, because the scores round to 100.0. Their order is effectively arbitrary.
`[Likely]` A joint count of 1 for Insulin Resistance × Islet Transplant over 2020–2026 looks like the keyword query under-captured. A MeSH query (`"Islets of Langerhans Transplantation"[MeSH] AND "Insulin Resistance"[MeSH]`) would test this in one call before the gap is cited anywhere.

## 5. Breaking news (last ~7 days)

1. **FDA approved finerenone (Kerendia) for CKD associated with T1D on 2026-09-17.** `[Likely — SILVER]` Source: trade press citing Bayer's release; the FDA label has not been read.
   The approval rests on FINE-ONE (n=242; UACR −25% vs. placebo at 6 months; *NEJM* 2026). That is a **surrogate endpoint**; FINE-ONE was not powered for kidney failure.
   Bayer calls it the first new therapy for T1D-CKD in more than 30 years. It is a repurposed indication extension, which makes it directly relevant to Tier 1 #4. Not in the trial corpus by name.
2. **FDA cleared the Beta Bionics Mint reusable insulin patch pump on 2026-09-15.** `[Likely — SILVER]` Device, Closed Loop AP axis.
3. **Correction to yesterday's report:** it listed the tirzepatide CV-risk indication as "pending 2H-2026." It was **approved 2026-08-28** (SURPASS-CVOT, noninferiority to dulaglutide). Insulin icodec is also **approved and on the US market** as of August. `[Likely — SILVER]`

No new Phase 3 readouts in the window. The retatrutide TRANSCEND/TRIUMPH data are from June (ADA).

## 6. Recommended actions

**P0 — Reschedule this monitor to ≥04:30 CDT.** Three consecutive reports have audited the previous day. Until then, compare all times in one clock (use `agent_state.last_run`, not mtimes vs. UTC).

**P0 — Repair the trials alias and refresh acquisition.** Run locally:
```
cd C:\Users\justi\OneDrive\Diabetes_Research\Analysis\Results
copy clinical_trials_snapshot_2026-09-06.json clinical_trials_latest.json
python baseline_clinical_trials.py
python hub_monitor.py
```

**P1 — Put `clinical_trials_latest.json` in scope for `report_freshness_audit`** (max age about 14 days). Today the gate cannot fail on the stalest data in the hub.

**P1 — Audit the trial query's coverage.** Test: after the fix, NCT06354660, NCT05929066, and FINE-ONE should all appear. If they don't, the "0 results posted / 0 Sana trials / 0 zimislecel" findings are artifacts of the query too.

**P1 — Still open from earlier reports:**
- Add VX-880/VX-264 aliases for zimislecel.
- Audit the three PubMed queries that return exactly 3.
- `git push` (no credential in the sandbox; the 09-22 repairs are unpushed).

**P2 — Update the tracker with the finerenone T1D-CKD approval.** Record it as a repurposing precedent, with the evidence level and the surrogate-endpoint caveat.

**P2 — Read these papers:**
- PMID 42763732 (CagriSema meta-analysis)
- PMID 42766004 (harmine and beta cells; repurposing × beta-cell regeneration)
- PMID 42764398 (multi-omics, Tier 1)

**P2 — Run the MeSH check on Insulin Resistance × Islet Transplant** before that gap is used anywhere.

---

## Sources

- [FDA approves finerenone for CKD associated with T1D — Patient Care Online, 2026-09-17](https://www.patientcareonline.com/view/fda-approves-finerenone-for-ckd-associated-with-type-1-diabetes)
- [Bayer press release (cited by above)](https://www.bayer.com/media/en-us/us-fda-approves-finerenone-for-new-indication-in-patients-with-chronic-kidney-disease-associated-with-type-1-diabetes/)
- [FDA clears Beta Bionics Mint — Patient Care Online, 2026-09-15](https://www.patientcareonline.com/view/fda-clears-beta-bionics-mint-reusable-insulin-patch-pump)
- [FDA expands tirzepatide label for CV risk — Patient Care Online, 2026-08-28](https://www.patientcareonline.com/view/fda-expands-tirzepatide-label-for-cardiovascular-risk-reduction-in-type-2-diabet)
- [Retatrutide Phase 3 data (TRIUMPH-1, TRANSCEND-T2D-1 NCTs) — Patient Care Online](https://www.patientcareonline.com/view/retatrutide-phase-3-data-show-weight-a1c-reductions-in-obesity-and-type-2-diabet)

*Local files read: `pubmed_recent_latest.json`, `pubmed_recent_snapshot_2026-09-20.json`, `literature_gap_report.md`, `literature_gap_data.json`, `clinical_trials_snapshot_2026-09-06.json`, `agent_state.json`, `report_freshness_audit.json`, `nct_identifier_audit.json`, `monitor_report_2026-09-22.md`, `repair_trial_registry_fields_20260922.py`.*
